June 2023 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.
September 2004 in “Evidencia actualizacion en la práctica ambulatoria” Using finasteride and doxazosina together works better for treating benign prostatic hyperplasia than using just one.
September 2023 in “Journal of the American Academy of Dermatology” 34 citations
,
May 1987 in “European Journal of Pediatrics” Buserelin safely and effectively suppresses early puberty, potentially improving final height.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
January 2011 in “Bloomsbury Academic eBooks”
12 citations
,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
July 2025 in “Colloids and Surfaces B Biointerfaces” A new method using hyaluronic acid liposomes improves Minoxidil's effectiveness and safety for hair growth treatment.
24 citations
,
July 2013 in “Oncologist” Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.
13 citations
,
November 2019 in “Scientific reports” Certain drugs change freshwater snail shells to a "banana" shape.
14 citations
,
June 2014 in “World Journal of Urology” The herbal combination of saw palmetto and stinging nettle reduces nighttime urination in men with urinary issues.
2 citations
,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
8 citations
,
August 1987 in “The Journal of Dermatology” BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.
March 2023 in “The Journal of Urology” Men with better urinary symptoms have a lower risk of death.
Fenugreek seeds and Butea monosperma flowers may help reduce hair loss from chemotherapy.
February 2023 in “Reactions Weekly” August 2004 in “Medisch-Farmaceutische Mededelingen” Long-term use of finasteride may cause breast cancer in men.
July 2025 in “International Journal of Health and Medicine” Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.
20 citations
,
June 1964 in “Archives of Dermatology” Systemic corticosteroids may effectively treat follicular mucinosis.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
January 2023 in “Springer eBooks”
The study introduces a finite element analysis (FEA)-guided co-design framework for developing separable bubble microneedles (BMNs) that optimize geometry and cavity parameters for controlled tip separation and robust insertion. The research demonstrated that minoxidil sulfate-loaded BMNs (MXS-BMNs) and insulin-loaded BMNs (INS-BMNs) achieved effective transdermal and sublingual delivery, respectively, with separation forces closely matching FEA predictions and axial strengths surpassing skin and mucosa penetration thresholds. In vivo tests showed MXS-BMNs significantly enhanced hair regrowth in mice, while INS-BMNs effectively lowered glucose levels in diabetic rats. This approach reduces empirical iteration, facilitating the rapid development of efficient microneedle systems for drug delivery.
5 citations
,
April 2024 in “Science China Materials”
31 citations
,
July 2017 in “Journal of the American Academy of Dermatology” Apremilast improved symptoms in patients with severe skin conditions.
October 2012 in “Sax's Dangerous Properties of Industrial Materials” 7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism”
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
August 2002 in “Inpharma Weekly”